Rare cancers are characterized by the National Institute of Health as those malignancies which inflect less than 40,000 people annually in the United States. Combined, all rare cancers account for about 25% of all cancer diagnoses. Unfortunately, research and development of new therapies for rare cancers is challenging, resulting in slow progress for new therapeutic approaches. While rare cancers exist in many organs throughout the body, all childhood cancers are considered rare.
-
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
The mammary gland is a unique organ that develops predominantly after birth and undergoes dramatic remodelling in reproductive phases. Macrophages have been implicated in mammary gland funct...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
The International Council for Standardization in Haematology (ICSH) is a nonprofit organization dedicated to providing open-access guidance documents to enhance the quality of laboratory tes...
Rapid access to high quality comprehensive coagulation test results is critical to patient care. In an environment where clinical laboratories constantly experience price and labor pressure,...
Achieving a diagnosis in rare disease patients can be challenging for even the most experienced clinician or scientist, creating a barrier to delivering truly personalised care. An exome seq...